Elizabeth Wagner

Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.

A. Naranjo, J. Gastier-Foster, J. Maris, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study.

James R. Anderson, J. Gastier-Foster, J. Dome, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group

A. Naranjo, J. Gastier-Foster, J. Maris, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical, pathological and loss of heterozygosity differences in Wilms tumors between Asian and non‐Asian children

B. Teh, A. Loh, A. Tan, 2018, International journal of cancer.

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations

M. Loh, B. Wood, S. Hunger, 2022, Blood.